Seabury Jamison, Varma Anika, Weinstein Jennifer, Rosero Spencer J, Engebrecht Charlotte, Khosa Shaweta, Zizzi Christine, Wagner Ellen S, Alexandrou Danae, Cohen Brittany L, Dilek Nuran, Heatwole John M, Lynch David R, Park Courtney C, Wells McKenzie, Subramony S H, Heatwole Chad R
Center for Health + Technology (JS, AV, JW, SJR, CE, SK, CZ, ESW, BLC, CRH); Department of Neurology (CZ, ND, CRH), University of Rochester, NY; Loyola University Chicago Stritch School of Medicine (DA), Maywood, IL; Cornell University (JMH), Ithaca, NY; Department of Neurology (DRL); Children's Hospital of Philadelphia (CHOP) (CCP, MW), PA; and Department of Neurology (SHS), University of Florida College of Medicine, Gainsville.
Neurol Clin Pract. 2024 Jun;14(3):e200303. doi: 10.1212/CPJ.0000000000200300. Epub 2024 May 10.
The Friedreich ataxia (FRDA) scientific community needs access to patient-centered outcome measures that satisfy regulatory guidelines and are capable of tracking clinically meaningful changes in FRDA disease burden. The objective of this research was to develop a novel, disease-specific caregiver-reported outcome measure for use in FRDA research and clinical care.
In prior work, we conducted qualitative interviews and a cross-sectional study of FRDA caregivers and patients to determine the symptoms of greatest importance to individuals with FRDA. We designed the Friedreich Ataxia Caregiver-Reported Health Index (FACR-HI) to serially measure the symptoms of greatest importance to patients and utilized factor analysis, beta testing, reliability testing, and cross-sectional subgroup analysis to further evaluate and optimize this disease-specific outcome measure.
The FACR-HI was designed to measure total disease burden and disease burden in 18 symptomatic domains. The FACR-HI total score demonstrated high internal consistency (Cronbach's α = 0.98) and test-retest reliability (intraclass correlation coefficient = 0.96). Beta interview participants found the FACR-HI to be highly relevant, comprehensive, and easy to use. FACR-HI total and subscale scores were associated with functional staging for ataxia scores and speech impairment.
Initial evaluation of the FACR-HI supports its content validity, test-retest reliability, and construct validity as a caregiver-reported outcome measure for assessing how pediatric individuals with FRDA feel and function. The FACR-HI provides a potential mechanism to quantify changes in multifactorial FRDA disease burden during future clinical trials.
弗里德赖希共济失调(FRDA)科学界需要能够获取符合监管指南且能够追踪FRDA疾病负担临床有意义变化的以患者为中心的结局指标。本研究的目的是开发一种用于FRDA研究和临床护理的新型、针对该疾病的照护者报告结局指标。
在之前的工作中,我们对FRDA照护者和患者进行了定性访谈和横断面研究,以确定对FRDA患者最重要的症状。我们设计了弗里德赖希共济失调照护者报告健康指数(FACR-HI),以连续测量对患者最重要的症状,并利用因子分析、β测试、信度测试和横断面亚组分析来进一步评估和优化这一针对该疾病的结局指标。
FACR-HI旨在测量18个症状领域的总疾病负担和疾病负担。FACR-HI总分显示出高内部一致性(克朗巴哈α系数=0.98)和重测信度(组内相关系数=0.96)。β访谈参与者发现FACR-HI高度相关、全面且易于使用。FACR-HI总分和子量表得分与共济失调评分和言语障碍的功能分期相关。
FACR-HI的初步评估支持其作为一种照护者报告结局指标的内容效度、重测信度和结构效度,用于评估患有FRDA的儿童的感受和功能。FACR-HI为量化未来临床试验中多因素FRDA疾病负担的变化提供了一种潜在机制。